Nurix Licenses a Drug Discovery Program to Sanofi Targeting Autoimmune Diseases

Nurix Therapeutics (NRIX) has licensed an undisclosed drug discovery program to Sanofi targeting a novel transcription factor for autoimmune diseases. The target, distinct from their STAT6 program, is a central regulator of inflammation identified using Nurix's DEL-AI platform.

The deal brings $15 million in license extension fees to Nurix, totaling $105 million received from Sanofi to date under their 2019 collaboration agreement. Nurix remains eligible for up to $465 million in additional milestone payments plus potential royalties. The company retains an option to co-develop and co-promote in the United States, with both parties splitting U.S. profits and losses.

This partnership expansion demonstrates the success of Nurix's DEL-AI discovery platform in developing innovative drugs for previously undruggable targets, while providing non-dilutive capital and pipeline expansion opportunities.

https://www.stocktitan.net/news/NRIX/nurix-licenses-a-drug-discovery-program-to-sanofi-targeting-a-novel-b1do4y227ler.html